BIOMAT Database Logo BIOMAT Database Logo

Interferon treatment of chronic active hepatitis C in patients with end-stage chronic renal failure. 1995

E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
Department of Internal Medicine, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey.

Alpha interferon has been shown to be effective in the treatment of chronic hepatitis C virus infection. We studied the efficacy of alpha 2a-interferon in chronic active hepatitis C patients with end-stage chronic renal failure (CRF). Thirteen patients with CRF and 12 patients with a normal renal function were included in the study. The patients received interferon 3 million units three times a week subcutaneously for 6 months. All patients with CRF and 6 patients without CRF had a complete response, defined as a decline in serum alanine aminotransferase levels to the normal range. One patient had a decrease in alanine aminotransferase of more than 50%, and 5 patients were nonresponders. A relapse was observed in 4 patients with and in 4 without CRF. Three patients had renal transplantation, and the alanine aminotransferase levels were normal after 12-14 months. This preliminary study shows that interferon is effective in the treatment of patients with chronic hepatitis C and CRF.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis.
April 2013, Journal of gastroenterology and hepatology,
E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
Active treatment of children with end-stage renal failure.
November 1982, The New Zealand medical journal,
E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
[Bilateral nephrectomy in patients with end-stage renal failure and chronic active pyelonephritis].
February 2016, Urologiia (Moscow, Russia : 1999),
E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
Treatment of chronic hepatitis C virus infection in patients with end-stage renal disease on hemodialysis.
September 2016, Clinical liver disease,
E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
[Selection of patients with chronic end-stage kidney failure for active treatment].
January 1981, Terapevticheskii arkhiv,
E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis.
April 2006, Liver international : official journal of the International Association for the Study of the Liver,
E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
February 2011, Journal of gastroenterology and hepatology,
E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
Treatment of chronic hepatitis C infection in patients with renal failure.
October 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
Treatment of chronic hepatitis C in patients with end-stage renal disease and hemophilia--the Singapore experience.
January 2006, Intervirology,
E Ozyilkan, and H Simşek, and B Uzunalimoğlu, and H Telatar
Management of Chronic Hepatitis C in End-stage Renal Disease.
April 2018, Journal of clinical gastroenterology,
Copied contents to your clipboard!